Author

C.-T. K. Tseng

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 5 Immunology· 3 Pharmacology & Toxicology· 2 Biochemistry· 1 Cell Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 12 Research Focus:host-pathogen & immune response· 7 Organism:mouse· 6 Research Focus:drug response / drug discovery· 5 Organism:human· 4 Assay:proteomics· 3 Assay:protein sequence· 1 Organism:virus· 1

Frequent Co-Authors

A. Drelich· 6 shared V. Tat· 5 shared B.-H. Peng· 4 shared J. Hsu· 3 shared J. Liu· 3 shared P. Saenkham-Huntsinger· 3 shared A. K. Drelich· 2 shared E. C. Vatansever· 2 shared

Activity by Year

2020-2023 · peak 6/yr

Co-Author Collaboration Network

10 top collaborators · 29 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

6 shared papersMicrobiology

A. Drelich

Mutual co-authors in cluster

Author profile →

12 papers

Recent·Most cited

Characterization of Unique Pathological Features of COVID-Associated Coagulopathy: Studies with AC70 hACE2 Transgenic Mice Highly Permissive to SARS-CoV-2 Infection

A. K. Drelich, K. Rayavara, J. Hsu, P. Saenkham-Huntsinger, B. M. Judy, V. Tat, T. G. Ksiazek, B.-H. Peng, C.-T. K. Tseng

This study characterizes the coagulopathy in AC70 hACE2 transgenic mice infected with SARS-CoV-2, revealing hypercoagulable states and ANXA2 system dysregulation.

bioRxiv · Oct 30, 2023Microbiology

Design of SARS-CoV-2 protease inhibitors with improved affinity and reduced sensitivity to mutations

M. Westberg, Y. Su, X. Zou, P. Huang, A. Rustagi, J. Garhyan, P. B. Patel, D. Fernandez, Y. Wu, L. Ning, A. Beck, M. Karim, C. Hao, P. Saenkham-Huntsinger, V. Tat, , M. Z. Lin

This study designs a SARS-CoV-2 protease inhibitor with improved affinity and reduced mutation sensitivity compared to existing drugs.

bioRxiv · Jul 19, 2023 · PreprintMicrobiology

A pan-variant mRNA-LNP T cell vaccine protects HLA transgenic mice from mortality after infection with SARS-CoV-2 Beta

B. Carter, P. Huang, G. Liu, Y. Liang, P. J. C. Lin, B.-H. Peng, L. McKay, A. Dimitrakakis, J. Hsu, V. Tat, P. Saenkham-Huntsinger, J. Chen, C. Kaseke, G. D. Gaiha, Q. Xu, , D. K. Gifford

A T cell vaccine based on conserved epitopes protects HLA transgenic mice from SARS-CoV-2 Beta variant mortality without inducing neutralizing antibodies.

bioRxiv · Sep 23, 2022Immunology

A bacteriophage-based, highly efficacious, needle and adjuvant-free, mucosal COVID-19 vaccine

J. Zhu, S. Jain, J. Sha, H. Batra, N. Ananthaswamy, P. B. Kilgore, E. Hendrix, Y. M. Hosakote, X. Wu, J. P. Olano, A. Kayode, C. L. Galindo, S. Banga, A. Drelich, V. Tat, , V. B. Rao

This paper develops a bacteriophage-based mucosal vaccine that induces strong immune responses and protects against SARS-CoV-2 and its variants without requiring needles or adjuvants.

bioRxiv · Apr 28, 2022Microbiology

Efficient Neutralization of SARS-CoV-2 Omicron and Other VOCs by a Broad Spectrum Antibody 8G3

H. Ma, C.-T. K. Tseng, H. Zong, Y. Liao, Y. Ke, H. Tang, L. Wang, Z. Wang, Y. He, Y. Chang, S. Wang, A. Drelich, J. Hsu, V. Tat, Y. Yuan, , J. Zhu

This study evaluates the neutralization efficacy of antibodies against SARS-CoV-2 Omicron and other variants, finding that antibody 8G3 maintains broad neutralizing activity while EUA antibodies lose effectiveness.

bioRxiv · Feb 25, 2022 · PreprintCell Biology

Comparison of Mucosal and Intramuscular Immunization against SARS-CoV-2 with Replication-Defective and Replicating Single-cycle Adenovirus Vaccines

M. A. Barry, H. Mudrick, E. McGlinch, B. Parrett, J. Hemsath, M. Barry, J. Rubin, C. Uzendu, M. Hansen, C. Erskine, V. VanKeulen, A. Drelich, C.-T. K. Tseng, C. S. Massey, M. Fida, , G. Olivier

This study compares mucosal and intramuscular immunization with replication-defective and replicating single-cycle adenovirus vaccines against SARS-CoV-2, showing that replicating vaccines generate stronger antibody responses.

bioRxiv · Apr 20, 2021 · PreprintImmunology

The Fc-mediated effector functions of a potent SARS-CoV-2 neutralizing antibody, SC31, isolated from an early convalescent COVID-19 patient, are essential for the optimal therapeutic efficacy of the antibody

C. E. Z. Chan, S. G. K. Seah, D. H. Chye, S. Massey, M. Torres, A. P. C. Lim, S. K. K. Wong, J. J. Y. Neo, P. S. Wong, J. H. Lim, G. S. L. Loh, D. L. Wang, J. D. Boyd-Kirkup, S. Guan, D. Thakkar, , B. J. Hanson

The paper identifies SC31, a potent SARS-CoV-2 neutralizing antibody, and shows that its Fc-mediated effector functions are critical for its therapeutic efficacy in vivo.

bioRxiv · Oct 26, 2020Microbiology

A nanoluciferase SARS-CoV-2 for rapid neutralization testing and screening of anti-infective drugs for COVID-19

P.-Y. Shi, X. Xie, A. E. Muruato, X. Zhang, K. G. Lokugamage, C. R. Fontes-Garfias, J. Zou, J. Liu, P. Ren, M. Balakrishnan, T. Cihlar, C.-T. K. Tseng, S. Makino, V. D. Menachery, J. P. Bilello

This paper develops a high-throughput assay using a nanoluciferase-modified SARS-CoV-2 virus to rapidly test neutralizing antibodies and antiviral drugs.

Nature Communications · Oct 15, 2020Peer-reviewedMicrobiology

Stapled peptides based on Human Angiotensin-Converting Enzyme 2 (ACE2) potently inhibit SARS-CoV-2 infection in vitro

F. Curreli, S. M. B. Victor, S. Ahmed, A. Drelich, X. Tong, C.-T. K. Tseng, C. D. Hillyer, A. K. Debnath

This study designs stapled peptides based on the ACE2 helix to inhibit SARS-CoV-2 infection, showing potent antiviral activity with no cytotoxicity.

bioRxiv · Aug 25, 2020Pharmacology & Toxicology

A Speedy Route to Multiple Highly Potent SARS-CoV-2 Main Protease Inhibitors

W. R. Liu, K. S. Yang, X. R. Ma, Y. Ma, Y. R. Alugubelli, D. A. Scott, E. C. Vatansever, A. K. Drelich, Z. Z. Geng, L. R. Blankenship, B. Sankaran, H. E. Ward, Y. J. Sheng, J. C. Hsu, K. K. Kratch, , H. S. Hayatshahi

This study designs and synthesizes potent SARS-CoV-2 main protease inhibitors, with some showing IC50 values below 100 nM and high virus inhibition potency in cell assays.

bioRxiv · Jul 28, 2020 · PreprintBiochemistry

Bepridil is Potent Against SARS-CoV-2 In Vitro

E. C. Vatansever, K. S. Yang, K. C. Kratch, A. Drelich, C.-C. Cho, D. M. Mellott, S. Xu, C.-T. K. Tseng, W. R. Liu

This study identifies bepridil as a potent inhibitor of SARS-CoV-2 MPro and virus entry, showing efficacy in vitro at low concentrations.

bioRxiv · May 23, 2020Pharmacology & Toxicology

Yeast-Expressed SARS-CoV Recombinant Receptor-Binding Domain (RBD219-N1) Formulated with Aluminum Hydroxide Induces Protective Immunity and Reduces Immune Enhancement

W.-H. Chen, X. Tao, A. Agrawal, A. Algaissi, B.-H. Peng, J. Pollet, U. Strych, M. E. Bottazzi, P. J. Hotez, S. Lustigman, L. Du, S. Jiang, C.-T. K. Tseng

This paper develops a SARS-CoV subunit vaccine using yeast-expressed RBD219-N1 with Alhydrogel® and shows it provides full protection against SARS-CoV challenge in mice.

bioRxiv · May 15, 2020Immunology